Who are NED Biosystems's investors?

NED Biosystems's investors include First Round Capital.

How much funding has NED Biosystems raised?

NED Biosystems has disclosed $3.5M raised across 2 rounds.

Where is NED Biosystems headquartered?

NED Biosystems is headquartered in Washington, US.

NED Biosystems

Washington, US · Delaware corporation · 1 known investors

Find your way into NED Biosystems

16 people in our graph share verified history with the NED Biosystems team — schools, employers, funds. One of them is your warm intro.

Zoe Angellunlockedknows Rebecca Lambert · together at Simmons University

×11knows the team · via Simmons University

NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.

Biotech Healthtech Medical Devices

Founders & leadership

Rebecca Lambert FounderRebecca Lambert founded NED Biosystems in 2008 after two decades investigating disease mechanisms in advanced cancers and identifying compounds targeting multiple cancer pathways, supported by collaborations with researchers including Judah Folkman at Harvard. She holds patents in angiogenic regulators and their applications to disease diagnosis and treatment.

Peter D'ErricoExecutive

Board

Mary G. DavisBoard director

Randall S. BarkoBoard director

Holly T. SargentBoard director

Investors · 1

First Round Capital✓ confirmed by NED BiosystemsSan Francisco · $100K – $20M

How we know: the company's own site · Not right? Tell us

Funding

SEC filings, press & company announcements

$3.5M disclosed across 2 rounds · 2015–2018

$2MSeries BAug 2018 · 2 sources
Source ↗

▶$1.5MraisedOct 2015 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Rebecca LambertExecutive Officer, Director
Peter D'ErricoExecutive Officer
Mary G. DavisDirector
Randall S. BarkoDirector
Holly T. SargentDirector

Offering amount: $2M
Amount sold: $1.5M
First sale: Oct 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

MD Anderson Cancer CenterUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.

Companies working in the same space as NED Biosystems.

In the news

NED Biosystems Raises $2 Million in Series B Financing Round and Appoints New CEO - BioSpacebiospace.com · Aug 2018

Frequently asked questions

What does NED Biosystems do?: NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.
Who are NED Biosystems's investors?: NED Biosystems's investors include First Round Capital.
How much funding has NED Biosystems raised?: NED Biosystems has disclosed $3.5M raised across 2 rounds.
Where is NED Biosystems headquartered?: NED Biosystems is headquartered in Washington, US.